IJF: Icon PLC: EGM Statement
UK Regulatory Announcement
ICON ANNOUNCES PUBLICATION OF EGM CIRCULAR IN RESPECT OF PROPOSED CONVERSION
TO DIRECT LISTING OF ITS SHARES ON NASDAQ
ICON plc, (NASDAQ: ICLR) (ISIN:IE0005711209), a global provider of outsourced
development services to the pharmaceutical, biotechnology and medical device
industries, today announced the publication and filing of a circular to
shareholders convening an extraordinary general meeting to be held at 3.00
p.m. on December 17, 2012 at ICON plc Headquarters, South County Business
Park, Leopardstown, Dublin 18, Ireland at which resolutions in connection with
the proposed replacement of ICON’s NASDAQ listing for ADSs with a direct
NASDAQ listing for ICON Shares will be considered and voted on.
The expected timetable in respect of the proposals is as follows:
Latest time and date for receipt of Forms of 13 December 2012
Proxy for Ordinary Shareholders for Extraordinary
General Meeting (6 p.m. GMT)
Extraordinary General Meeting 17 December 2012 (3 p.m.
Expected last day of dealings in Shares on Irish 29 January 2013
Expected date of Irish Stock Exchange Delisting 30 January 2013
with effect from 6.30 a.m. (GMT)
Expected date of commencement of direct trading 4 February 2013
of Shares on NASDAQ
A copy of the Circular is available in the investor relations section of
ICON’s website at http://investor.iconplc.com/proxy.cfm.
A copy of the Circular is also being submitted to the Irish Stock Exchange,
and will shortly be available for inspection at:
Company Announcements Office,
Irish Stock Exchange,
28 Anglesea Street,
Defined terms used in this announcement have the same meaning as in the
Circular unless otherwise stated.
The information contained in this release is as of November 16^th 2012. ICON
assumes no obligation to update forward-looking statements contained in this
release. A description of risks and uncertainties relating to ICON and its
business can be found in ICON’s Annual Report and Form 20-F for the fiscal
year ended December 31, 2011 and in its Reports of Foreign Issuer on Form 6-K
filed with the US Securities and Exchange Commission.
ICON plc is a global provider of outsourced development services to the
pharmaceutical, biotechnology and medical device industries. The company
specialises in the strategic development, management and analysis of programs
that support clinical development - from compound selection to Phase I-IV
clinical studies. With headquarters in Dublin, Ireland, ICON currently,
operates from 82 locations in 40 countries and has approximately 9,430
employees. Further information is available at http://www.iconplc.com.
Source: ICON plc
Investor Relations 1-888-381-7923 or
Brendan Brennan Chief Financial Officer + 353 –1-291-2000
Sam Farthing VP Investor Relations + 353 –1-291-2000
All at ICON
Press spacebar to pause and continue. Press esc to stop.